Document Detail

Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure.
MedLine Citation:
PMID:  9456189     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To evaluate the possibility of predicting development of heart failure, we monitored left ventricular ejection fraction (LVEF) in addition to demographic data in patients with advanced breast cancer treated with epirubicin. METHODS AND RESULTS: LVEF determination by radionuclide angiocardiography was performed serially before, during, and after treatment with 130 mg epirubicin/m2 every 3 weeks until disease progression or a cumulative dose of 1000 mg/m2 was reached (or heart failure occurred). Among 67 patients, heart failure developed in eight (12%). Age was 5 to 8 years greater and baseline LVEF was 7% less (95% confidence interval 3% to 13%) in patients who had heart failure than in the remaining patients. LVEF was slightly reduced in all patients during treatment. Three combined criteria, age > or =50 years, baseline LVEF < or =0.60, and decrease in LVEF to 0.50, had a positive predictive value of 70% (95% confidence interval 35% to 93%) and a negative predictive value of 98% (95% confidence interval 90% to 100%) with respect to development of heart failure. Conventional LVEF criteria were of less diagnostic value. CONCLUSIONS: Our results indicate that age and baseline LVEF determination mark a group of patients at high risk for development of epirubicin-induced heart failure. Monitoring of serial LVEF is indicated during treatment of these patients.
B Schaadt; H Kelbaek
Related Documents :
23238539 - Overview of large animal myocardial infarction models (review).
18324939 - Validation of the chinese version of the macnew heart disease health-related quality of...
19275979 - Comparing administration of questionnaires via the internet to pen-and-paper in patient...
20869649 - Pathophysiology and management of heart failure in repaired congenital heart disease.
20486829 - Growth hormone and testosterone in heart failure therapy.
11738219 - Chemoreflexsensitivity in chronic heart failure patients.
2519899 - Aspirin, platelets and prevention of vascular disease.
16782719 - Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acut...
17478179 - Time to reperfusion in acute myocardial infarction. it is time to reduce it!
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology     Volume:  4     ISSN:  1071-3581     ISO Abbreviation:  J Nucl Cardiol     Publication Date:    1997 Nov-Dec
Date Detail:
Created Date:  1998-03-05     Completed Date:  1998-03-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9423534     Medline TA:  J Nucl Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  494-501     Citation Subset:  IM    
Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antibiotics, Antineoplastic / adverse effects*
Breast Neoplasms / drug therapy*
Epirubicin / adverse effects*
Heart / radionuclide imaging*
Heart Failure / chemically induced*
Middle Aged
Stroke Volume / drug effects*
Ventricular Function, Left / drug effects*
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 56420-45-2/Epirubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic value of stress myocardial perfusion single photon emission computed tomography imaging i...
Next Document:  Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment...